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1. Introduction 
1.1 Breast cancer classification 
Breast cancer is one of the most common cancers among women worldwide and 
approximately one-third of women diagnosed will eventually develop metastases and die 
(Jemal et al, 2010). Breast cancer is heterogeneous at the molecular, histopathologic and 
clinical levels and is commonly classified into several categories according to multiple 
schemes, each based on different criteria. A typical description of breast cancer can be 
comprised of tumor grade, histologic type, tumor stage, and the expression of proteins and 
genes etc. (McSherry et al, 2007). Normal non-cancerous cells are differentiated and have 
specific cell shapes and functions; whereas, cancer cells lose differentiation (de-
differentiate), have less uniform nuclei, and exhibit uncontrolled cell division. Pathologists, 
therefore, determine breast cancer by grade according to the degree of differentiation of cells 
compared to normal breast cells: highly differentiated (low grade), moderately 
differentiated (intermediate grade), and poorly differentiated (high grade). Cancers 
classified as high grade generally have a worse prognosis (McSherry et al, 2007). The 
majority of breast cancers are derived from the epithelium lining the ducts or lobules of the 
breast. They can be classified histologically according to characteristics seen upon light 
microscopy of biopsy specimens. Histologic classification is divided into: ductal carcinoma 
in situ (DCIS), invasive ductal carcinoma, and invasive lobular carcinoma (McSherry et al, 
2007). Breast cancer can further be classified using the TMN Classification of Malignant 
Tumors, TMN stage is based on tumor size, lymph node micrometastasis, and 
macrometastasis, where ‘T’ describes tumor size; ‘N’ indicates whether or not the tumor has 
spread to the lymph nodes; and ‘M’ indicates whether or not distant metastasis has 
occurred. Larger tumor size with lymph nodal spread and distal metastasis has a worse 
prognosis (Gonzalez-Angulo et al, 2007). Expression of certain proteins and genes can also 
be used to classify breast cancer (McGrogan et al, 2008; Stickeler et al, 2009). Whole-genome 
analysis using expression microarray and immunohistochemical analysis has revolutionized 
the understanding of breast carcinomas in recent years, and led to the discovery of five 
distinct subtypes of breast carcinomas (luminal A, luminal B, HER-2 overexpression, basal-
like, and normal-like), each with unique recognizable phenotypes and clinical outcomes 
(McGrogan et al, 2008; Stickeler et al, 2009). By using classification to characterize each 
cancer patient, it may help select the suitable treatment strategies to achieve an optimal 
outcome and increase therapeutic efficacy. 
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2. Breast cancer metastasis 
In the United States, about 178,480 new cases of invasive breast cancer were diagnosed in 
2007 and approximately 40,460 women died (Jemal et al, 2007). In 2010, about 207,090 new 
breast cancer cases were diagnosed and 39,840 died (Jemal et al, 2010). The breast cancer 
incidence rate has been decreasing in the USA since 1999 and the majority of 40,000 women 
died each year were due to breast cancer metastasis (Giordano & Hortobagyi, 2003; Jemal et 
al, 2010). Cancer metastasis is a complex process that includes intercellular and intracellular 
signaling, activation, adhesion, migration and invasion (Im et al, 2004; Lee et al, 2006). 
Epithelial-to-mesenchymal transition (EMT) is also thought to be involved in cancer 
metastasis. EMT may promote cancer-cell progression and invasion into the surrounding 
microenvironment. Historically, epithelial and mesenchymal cells are distinct in their 
unique cellular appearance and the morphology of the multicellular structures they create 
(Shook & Keller, 2003). A typical morphology of epithelium is sheeted and thick with 
individual epithelial cells abutting each other in a uniform array. Cell-to-cell junctions and 
adhesions between neighboring epithelial cells hold cells tightly together and inhibit the 
movement of individual cells away from the epithelial monolayer. Mesenchymal cells, on 
the other hand, possess usually a more extended and elongated shape and do not exhibit 
either a regimented structure or tight intracellular adhesion. Mesenchymal cells are irregular 
in shape and not uniform in composition or density. Adhesions between mesenchymal cells 
are not as strong as those of their epithelial counterparts, allowing for increased migratory 
capacity. The transformation of an epithelial cell into a mesenchymal cell not only alters 
cellular morphology, architecture, adhesion capacity, and migration capacity but also 
enhances capability of the cell to metastasize (Shook & Keller, 2003). Conversely, the 
transformation of a mesenchymal cell into an epithelial cell (MET) may prevent cell invasion 
and suppress cell metastatic ability. 
3. Breast cancer therapy  
To date, adjuvant and neo-adjuvant therapies are commonly used in cancer metastasis 
therapy (McGrogan et al, 2008). Currently, there are three main groups of medications used 
for adjuvant breast cancer treatment: (1) hormone blocking therapy; (2) chemotherapy; and 
(3) monoclonal antibody therapy (McGrogan et al, 2008). The cell surfaces of some breast 
cancers are estrogen receptors positive (ER+) and/or progesterone receptors positive (PR+) 
and the cells require estrogen to continue growing. These cancers can be treated with drugs 
that block either the hormone receptors, such as tamoxifen or the production of estrogen, 
such as anastrozole (Arimidex) or letrozole (Femara). The drugs that inhibit estrogen 
production are only suitable for post-menopausal patients (Gonzalez-Angulo et al, 2007). 
Combination chemotherapy is predominately used for patients at stages 2-4, being 
particularly beneficial in ER-breast cancer. One of the most common treatments is 
cyclophosphamide plus doxorubicin (Adriamycin) which destroys rapidly growing or 
replicating cancer cells by causing DNA damage; however, these drugs also damage normal 
cells causing serious adverse effects. Damage to heart muscle is the most dangerous 
complication associated with doxorubicin. Taxane drugs such as paclitaxel, a microtubule-
stabilizing agent that interferes with spindle microtubule dynamics causing cell-cycle arrest 
and apoptosis through interaction with ǃ-tubulin (Bergstralh & Ting, 2006), is also used in 
the breast cancer metastasis therapy. However, resistance to paclitaxel is common and there 
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is a need to identify patients most likely to respond to treatment (McGrogan et al, 2008). 
Other treatments like methotrexate and fluorouracil are also used in chemotherapy. 
Approximately 15-20% of breast cancers have an amplification of the HER-2/neu gene or 
overexpression of its protein product. This receptor is a marker for poor prognosis that is 
associated with increased disease recurrence during the period of cancer therapy (Brown et 
al, 2008). Trastuzumab (Herceptin), a humanized monoclonal antibody that specifically 
binds to the extracellular domain of the HER-2 receptor, has improved the 5-year disease 
free survival of stage 1-3 HER-2+ breast cancers to about 87%. However, about 2% of 
patients suffer significant heart damage after Herceptin treatment (Brown et al, 2008). 
Trastuzumab has also been used in combination with doxorubicin and proven to be highly 
effective for metastatic breast cancer patients with HER-2 over-expressing tumors. However, 
this regimen causes severe cardiac toxicity in 27% of treated patients when the two 
substances are given concurrently (Stickeler et al, 2009). Lapatinib (Tykerb, 
GlaxoSmithKline) is an orally active small molecule that inhibits the tyrosine kinases of 
HER-2 and epidermal growth factor receptor type 1 (EGFR). In preclinical studies, lapatinib 
showed no cross-resistance with trastuzumab (Jahanzeb, 2008).  
Conventional radiotherapy is usually given after surgery to destroy remaining tumor cells 
that may have escaped surgery. Recently, radiotherapy has also been given at the time of 
surgery and found to reduce the risk of recurrence by 50-66% (Belletti et al, 2008). Despite 
such improvements in treatment modalities, there is still a high rate of failure among 
adjuvant interventions mainly due to tumor invasion and metastasis. Therefore, the search 
for new therapeutic targets and the development of new inhibitors of tumor cell 
resettlement and metastatic growth continues.  
4. Surface membrane integrins as potential drug-discovery targets 
It is well known that cell activation, migration, proliferation, and differentiation require 
direct contact between cells and the extracellular matrix (ECM). Cell-to-cell and cell-to-
matrix interactions are mediated by the integrin, selectin, cadherin and/or immunoglobulin 
families and several studies have focused on investigating cancer therapies based on the 
integrin superfamily. Integrin expression on cancer cells is frequently associated with cancer 
progression and metastasis; therefore, targeting small-molecule antagonists of the integrin 
superfamily provides an opportunity to suppress cancer development and metastasis 
(Mullamitha et al, 2007). ǃ1 integrin, which frequently aberrantly expressed in human breast 
carcinomas, has been verified to play a central role in metastasis and contribute to growth 
factor receptor signaling. Inhibition of the 1 integrin signaling pathway has been shown to 
abolish the formation of metastasis in breast and gastric cancer models. Additionally, the 1 
integrin signaling pathway also plays a significant role in mediating resistance to cytotoxic 
chemotherapies by enhancing cell survival in hematologic malignancies, lung, and breast 
cancers (Lu et al, 2008). Recent studies have shown that ǂ1ǃ1, ǂ2ǃ1, and ǂ3ǃ1 integrins 
regulate hepatocarcinoma cell invasion, angiogenesis of human squamous cell carcinoma, 
and increase migration and invasion of malignant glioma, melanoma and mammary 
adenocarcinoma cells, respectively. Expression of ǂ5ǃ1 integrin in colon cancer cells 
decreases HER-2-mediated proliferation (Kuwada et al, 2005). Loss of the ǂ7ǃ1 integrin in 
melanoma increases highly tumorigenic and metastatic phenotypes (Ziober et al, 1999). 
Several preclinical and clinical trials have shown that some integrin targeting antibodies can 
effectively block tumor growth and metastasis. These antibodies include MEDI-522 (vitaxin) 
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against ǂvǃ3 integrin (Brooks et al, 1994), CNTO 95 against both ǂvǃ3 and ǂvǃ5 integrins 
(Mullamitha et al, 2007), 17E6 against ǂvǃ3, ǂvǃ5, and ǂvǃ1 integrins (Mitjans et al, 2000), 
LM609 against v3 integrin, and Tysabri (natalizumab) against ǂ4 integrins (O'Connor, 
2007). In addition, 1 integrins possess a RGD-binding region, therefore, based mainly on 
their RGD containing peptides and RGD peptidomimetics, some small molecule integrin 
antagonists have also shown potent inhibition of angiogenesis (Kumar et al, 2001). Both 
fibronectin and its receptor integrin ǂ5ǃ1 directly regulate angiogenesis (Kim et al., 2000). 
Thus, antagonist(s) of ǂ5ǃ1 integrin might be useful targets for the inhibition of 
angiogenesis associated with human tumor growth, and neovascular-related ocular and 
inflammatory diseases (Pasterkamp et al, 2003; Suzuki et al, 2007). Further, our own 
studies recently found that fibrillar bovine serum albumin (F-BSA) induced apoptosis in 
human breast duct carcinoma cell line T47D, and fibrillar fibronectin (F-FN) induced 
apoptosis in human breast cancer cell line MCF-7. F-BSA and F-FN induced BHK-21 cell 
(baby hamster kidney cell) apoptosis through negatively regulating the 
integrin/FAK/Akt/GSK-3ǃ signaling pathway and activating SHP-2 and RhoA/ROCK 
(Huang et al, 2009; Huang et al, 2010). Together these results suggest that inhibition of the 
1 integrin signaling pathway may provide a promising therapeutic approach to breast 
cancer metastasis. 
5. Formation and purification of fibrillar human serum albumin 
Some diseases like Alzheimer’s disease, transmissible spongiform encephalopathies, 
pancreatic islet amyloidosis, and familial amyloidosis are caused primarily by amyloid-like 
fibrils aggregation in organs and in the circulation (Jackson & Clarke, 2000). Recently, it has 
been documented that amyloid-like fibrils are cytotoxic to neuronal cells, BHK-21 cells, 
SKOV-3, and MCF-7 cancer cells (Gharibyan et al, 2007; Su & Chang, 2001; Zamotin et al, 
2006). Whether the fibrillar proteins may be used as anti-cancer drugs in the cancer 
therapies is largely unclear. We have developed a novel process to convert globular 
proteins, bovine serum albumin and fibronectin, to fibrillar forms using detergent assisted 
refolding chromatography (Huang et al, 2009; Huang et al, 2010). This procedure is easier to 
perform than other methods reported to convert proteins to fibrillar structures such as 
glycation, sonication, or high temperature incubation (Azakami et al, 2005; Taboada et al, 
2006). Fibrillar protein F-BSA induced apoptosis in human breast duct carcinoma cell line 
T47D, and F-FN induced apoptosis in human breast cancer cell line MCF-7 suggesting that 
fibrillar proteins may have therapeutic effect in human breast cancer cells. We thus further 
investigated the effects of the fibrillar form of human serum albumin (F-HSA) on the 
malignant breast cancer cell lines, TS/A and MDA-MB-231. We chose F-HSA for further 
study for two reasons: first, because F-HSA is less likely to provoke an immune response in 
the human body; and second, because HSA is easier to obtain and less costly than FN. We 
produced F-HSA using the same process as was used to produce F-BSA. In brief, 20 mg of 
HSA from human serum was dissolved in 10 ml of PBS with 1% SDS (w/v). The HSA 
solution was sonicated for 5 minutes and subsequently applied to a Superdex-200 column 
previously equilibrated with the eluting buffer (25 mM Tris-HCl, pH 8.0, 1 mM EDTA, 0.1 M 
NaCl, and 0.05% SDS). The fractions that contained HSA were pooled and dialysed against 
PBS to remove SDS. The yield of the F-HSA was about 67% (Fig. 1). The F-HSA produced 
was then tested for fibrillar structure by transmission electron microscopy (TEM). For TEM 
analysis of F-HSA, 2 mg/ml of protein was applied to a 300-mesh carbon-coated copper 
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grid. Excess samples were removed, and the grid was air dried. The protein-bearing grid 
was negatively stained with 1% (w/v) phosphotungstic acid for 1 minute. Transmission 
electron micrographs were observed at 20,000–150,000× magnification at 75 kV on a Hitachi 
H-7000 electron microscope. TEM analysis showed that F-HSA did indeed have a fibril 
structure (Fig. 2).  
 
 
 
 
Fig. 1. Elution profile of F-HSA from a Superdex-200 column. HSA (2 mg/ml dissolved in 
PBS containing 1% SDS) was applied to a Superdex-200 column and eluted at a rate of 1 
ml/min with a buffer solution containing 0.05% SDS. Arrow shows F-HSA. 
Specific binding to Thioflavin T (ThT) is one of the characteristics of amyloid-like proteins. 
ThT fluorescence assay was, thus, used to identify amyloid-like fibrils (LeVine, 1999). Like 
A (1-42), which is known to have fibrillar structure and was used as a positive control, F-
HSA obtained from the Superdex-200 column exhibited a gradual dose-dependent increase 
in ThT fluorescence level (Fig. 3).  
6. Effects of F-HSA on cell viability 
Previously, we demonstrated that F-BSA and F-FN induced apoptosis in the less malignant 
T47D and MCF-7 breast cancer cell lines, respectively (Huang et al, 2009; Huang et al, 2010). 
In this study, we examine whether F-HSA induced cytotoxicity in the more malignant breast 
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cancer cell lines, TS/A and MDA-MB-231, using a 3-(4,5-cimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT)-colorimetry assay to measure the cell viability (MERCK, 
Darmstadt, Germany). TS/A, a murine mammary adenocarcinoma cell line that is estrogen 
dependent, was cultured in Dulbecco’s modified Eagle’s medium (DMEM; GIBCO); and 
MDA-MB-231 (ATCC HTB-26™), a metastatic human breast cancer cell line that is estrogen 
independent, was cultured in DMEM/F12 medium (GIBCO). In brief, 2  104 breast cancer 
cells were incubated in serum-free medium and treated with serial dilutions of F-HSA. After 
incubation for 24 hours to allow the drug to take effect, 10 l MTT solution was added to 
each well. After incubation at 37°C in 5% CO2 for another 2 hours to allow the MTT solution 
to be metabolized, formazan (MTT metabolic product) was resuspended in 200 ul DMSO. 
Finally, the proportions of surviving cells were determined by optical density (570 nm test 
wavelength, 630 nm reference wavelength). The percentage of surviving cells was calculated 
as (O.D.treatment/O.D.control)  100%, and the percentage of growth inhibition was calculated 
as [1 - (O.D.treatment/O.D.control) ]  100%. IC50 value is the concentration at which the reagent 
produces 50% inhibition of cellular viability. F-HSA inhibited growth of the breast cancer cell 
lines TS/A and MDA-MB-231 in a dose dependent manner with IC50 values of 0.15 and 0.48 
μM, respectively (Fig. 4). F-HSA at concentrations over 0.4 μM induced dose-dependent 
cytotoxicity in both TS/A cells and MDA-MB-231 cells, whereas concentrations of 0.1-0.2 
μM did not affect cell viability significantly.  
 
 
2 microns
 
Fig. 2. Ultra-structures of F-HSA were observed by TEM. F-HSA was applied to a 300-mesh 
carbon-coated copper grid then the grid was air-dried. The F-HSA-bearing grid was 
negatively stained with 1% (w/v) phosphotungstic acid. Finally, transmission electron 
micrographs were observed at 20,000–150,000× magnification at 75 kV on a Hitachi H-7000 
electron microscope. Arrows show F-HSA. 
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Fig. 3. ThT fluorescence assay of F-HSA. For fluorescence measurements, increasing 
concentrations of proteins were incubated with 20 μM ThT for 1 h at room temperature, and 
fluorescence was measured in triplicate on a Wallac Victor2 1420 Multilabel Counter (Perkin 
Elmer Life Science, Waltham, MA, USA). Excitation and emission wavelengths were 430 nm 
and 486 nm, respectively. ThT background signal from buffer solution was subtracted from 
the corresponding measurements. A (1-42) was used as a positive control. 
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(a)      (b) 
Fig. 4. Effect of F-HSA on viability of TS/A (A) and MDA-MB-231 cells (B). 
To understand the effects of F-HSA on cell morphology and MET in TS/A cells and MDA-
MB-231 cells, breast cancer cells were treated low concentrations of F-HSA and cell 
morphology was observed under light microscopy. F-HSA induced a morphological 
alteration in cells, from a fibroblast-like shape to a round shape (Fig. 5). We also examined 
whether F-HSA suppressed breast cancer-cell migration at non-cytotoxic concentrations by 
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wound-healing assay. TS/A and MDA-MB-231 cells were plated onto six-well tissue culture 
dishes in complete tissue culture medium until they formed a confluent monolayer. The cell 
monolayer was scratched with a sterile pipette tip to generate a wound (width 2 mm). The 
remaining cells were washed three times with culture medium to remove cell debris. The 
medium was immediately replaced with serum-free medium with 0.1 or 0.2 µM of F-HSA, 
and cultured at 37°C for 24 hours. Spontaneous cellular migration was then monitored at 0 
hours (immediately after wounding) and 24 hours (the end of F-HSA treatment) using and 
inverted microscope (Axiovert 200M; Zeiss) at 100× original magnification. The extent of 
wound healing was determined by the distance (migrating distance) traversed by cells 
migrating into the denuded area. F-HSA at concentrations of 0.1 to 0.2 µM suppressed cell 
migration of both TS/A and MDA-MB-231 cells (Figs. 6-7). 
 
 
Fig. 5. F-HSA induced morphological alterations and mesenchymal-to-epithelial transition 
in breast cancer cells. After 0.1 μM and 0.2 μM of F-HSA treatment at 37°C for 24 h, cell 
morphology was observed under light microscopy. Scale bar, 5 μm 
 
 
 
Fig. 6. F-HSA suppressed TS/A cell migration in a breast cancer cell wound-healing assay. 
After 0.1 μM and 0.2 μM of F-HSA treatment at 37°C for 24 h, cell migration was observed 
under light microscopy.  
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Fig. 7. F-HSA suppressed MDA-MB-231 cell migration in a wound-healing assay. After  
0.1 μM and 0.2 μM of F-HSA treatment at 37°C for 24 h, cell migration was observed under 
light microscopy. 
7. F-HSA suppresses breast cancer cell migration via 1 integrin signaling 
pathway 
Cell surface receptors mediate cell-to-matrix and cell-to-cell interactions. Integrins are a 
large family of heterodimeric transmembrane receptors that mediate cell-ECM interactions. 
In eukayotic cells, integrins consist of 18 ǂ subunits and 8 ǃ subunits that form 24 different 
ǂǃ integrins. The particular combination of  and ǃ subunits in integrin dimers determines 
their specificity for ligands, which include most of the ECM proteins such as FN and 
collagen (Plow et al, 2000). Upon activation by ECM proteins, integrins mediate cellular 
adhesion, migration, survival, and proliferation (Ginsberg et al, 2005). Integrin signaling is 
activated by ECM proteins or growth factors through focal adhesion kinase (FAK), PI3K, 
and Akt, a major downstream target of PI3K signaling, known to be involved in various 
cellular processes such as cell survival, cell cycle, metabolism, protein synthesis, and 
transcriptional regulation (Mitra & Schlaepfer, 2006). We showed that fibrillar proteins 
induced cellular apoptosis (Huang et al, 2009; Huang et al, 2010). The mechanism of the 
cytotoxic effects of F-BSA in BHK-21 cells (baby hamster kidney cell) was due to modulation 
of the 51 integrin/FAK/Akt/GSK-3ǃ/caspase-3 signaling pathway. Furthermore, F-FN 
induced cytotoxicity via activating SHP-2 and RhoA/ROCK, and deactivation of Akt/GSK-
3. Taken together these findings suggested that ǃ1 integrin may play a critical role in 
mediating cancer growth and metastasis. Therefore, we measured the proportion of 5 
integrin+ cells or 1 integrin+ cells in TS/A and MDA-MB-231 cells by flow cytometry. First, 
TS/A or MDA-MB-231 cells were collected and washed with 1× PBS three times. Then, 
specific monoclonal antibodies for 5 integrin-FITC and 1 integrin-FITC were added and 
co-incubated with cells (1 × 105/ml) at 4°C for 30 minutes. Cells were then washed three 
times using 1× PBS and finally stained with 5 μg/ml propidium iodide (PI) at 4°C for 10 
minutes to exclude dead cells. Cell viability was determined using a flow cytometer 
(FACSCalibur; BD Bioscience) and CellQuest software. Data showed that 58.67% and 66.19% 
of TS/A cells were 5 integrin+ and 1 integrin+, respectively. 42.99% and 97.65% of MDA-
MB-231 cells were 5 integrin+ and 1 integrin+, respectively (Table 1). Blocking 1 integrin 
signaling pathway with a specific mAb (mouse anti-human integrin beta1 monoclonal 
antibody; Millipore) could reverse F-HSA’s effect on TS/A and MDA-MB-231 breast cancer 
cell migration (Fig. 8). Taken together, these results indicated that the suppression of breast 
cancer migration by F-HSA may be mediated by binding of 1 integrin. 
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 5 integrin 1 integrin 
TS/A 58.67 (%) 66.19 (%) 
MDA-MB-231 42.99 (%) 97.65 (%) 
Table 1. Percentages of 5 integrin+ cells and 1 integrin+ cells in TS/A and MDA-MB-231 
cells. 
 
Fig. 8. Blocking the 1 integrin signaling pathway with a specific mAb (mouse anti-human 
integrin beta1 monoclonal antibody) reversed the effect of 0.2 M F-HSA on TS/A and 
MDA-MB-231 breast cancer cell migration. 
8. Conclusion 
The search for novel therapeutic targets and the development of inhibitors of cancer metastasis 
is an ongoing challenge. Herein, we used a detergent assisted refolding chromatography 
process to convert globular HSA into fibrillar F-HSA. Unlike globular HSA, this novel F-HSA 
caused cell death, reversed EMT, and suppressed breast cancer cell migration through 
targeting 1 integrin signaling pathway. These important findings may be useful for the 
development of better therapeutics for the intervention of breast cancer metastasis.  
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